Torrent Pharmaceuticals expands voluntary recall of losartan

Torrent Pharmaceuticals has expanded its voluntary recall of its losartan potassium tablets to include five additional lots due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid, or NMBA, according to an FDA press release.

The expanded recall impacts three lots of losartan potassium tablets and two lots of losartan potassium/hydrochlorothiazide (HCTZ) combination tablets.